TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33225383
Drug: Impaired Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired Activity of Daily Living scale score
Study: 33225717
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose intake during an oral glucose tolerance test, assessed by indirect calorimetry for measuring diet-induced thermogenesis (DIT).
Study: 33225952
Drug: High-dose thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thromboprophylaxis (≥ 175 IU/kg of body weight tinzaparin or ≥ 200 IU/kg of body weight dalteparin)
Study: 33225952
Drug: Medium-dose thromboprophylaxis
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose thromboprophylaxis (> 4500 IU but < 175 IU/kg of body weight tinzaparin or > 5000 IU but < 200 IU/kg of body weight dalteparin)
Study: 33225952
Drug: Low-dose thromboprophylaxis
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose thromboprophylaxis (2500-4500 IU tinzaparin or 2500-5000 IU dalteparin)
Study: 34875111
Drug: High-dose thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thromboprophylaxis
Study: 33225952
Drug: Medium-dose thromboprophylaxis
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose thromboprophylaxis
Study: 33225952
Drug: Low-dose thromboprophylaxis
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose thromboprophylaxis
Study: 33226334
Drug: Opioid use
Normalized name: Modia Opioid Use Disorder Support Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid use (measured in lowest recommended dosage units)
Study: 33227125
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg/d
Study: 33227125
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg/d (prior RTX treatment)
Study: 33227125
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg/d (prior RTX-CIT treatment)
Study: 33227125
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg/d (extranodal subtype)
Study: 33227125
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg/d (nodal subtype)
Study: 33227125
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg/d (splenic subtype)
Study: 33227283
Drug: Biologics (n=642)
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics (n=642)
Study: 33227283
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (n=227)
Study: 33227350
Drug: Adequate first-line
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adequate first-line antibiotic treatment of proven bacterial infections
Study: 33229362
Drug: Rilonacept 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept 320 mg SC load/160 mg SC weekly maintenance
Study: 34465599
Drug: LY3300054 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3300054 monotherapy
Study: 33229508
Drug: Expanded CD4
Normalized name: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine
DrugBank: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine (DB19219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expanded CD4 T cells cultured with high dose of interleukin-2 for up to 5 weeks
Study: 33230035
Drug: Compensation training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compensation training and substitution therapies
Study: 33230103
Drug: CD19-specific chimeric
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-specific chimeric antigen receptor T cell (CD19 CAR T) therapy
Study: 33230210
Drug: peposertib 100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: peposertib 100-200 mg once daily or 150-400 mg twice daily (BID) in 21-day cycles
Study: 33230210
Drug: peposertib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: peposertib 400 mg BID (RP2D)
Study: 33230962
Drug: Ketosis (βHB:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketosis (βHB: 1.24±0.82 mmol/L in fasting)
Study: 33231487
Drug: ACE-I/ARB therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-I/ARB therapy
Study: 33231487
Drug: ACE-I/ARB therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-I/ARB therapy during hospitalization
Study: 33234651
Drug: Serological tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serological tests for COVID-19 (IgM and IgG antibodies)
Study: 33234651
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of IgM and IgG antibodies
Study: 33234662
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tumour infiltrating lymphocytes (TIL) and anti-PD-1
Study: 33234662
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TIL, pegylated-interferon-alpha (PEG-IFNa) and anti-PD-1
Study: 33237534
Drug: INL-001 implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: INL-001 implants (3 implants, each containing 100 mg bupivacaine HCl)
Study: 33237534
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine HCl infiltration (175 mg)
Study: 33239226
Drug: 1-dose Havrix
Normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-dose Havrix vaccine
Study: 33239226
Drug: 2-dose Havrix
Normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose Havrix vaccine
Study: 33239228
Drug: qHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: qHPV vaccine (3 doses on Day 1, Month 2, Month 6)
Study: 33239899
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance defined by Homeostatic Model Assessment for insulin-resistance cut-offs that accommodated pubertal and gender differences.
Study: 33239899
Drug: Anthropometric, metabolic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthropometric, metabolic, intake-related variables, and 55 single nucleotide polymorphisms related to NAFLD and choline metabolism were evaluated.
Study: 33240121
Drug: Transcranial Direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Direct Current Stimulation (tDCS) as an add-on treatment to Cognitive-Behavior Therapy (CBT)
Study: 33240257
Drug: Western Equine
Normalized name: Western equine encephalitis virus Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western Equine Encephalitis Vaccine (WEEV; WEE TSI-GSD 210)
Study: 33240282
Drug: IO103 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO103 vaccine with Montanide ISA 51 adjuvant, administered subcutaneously up to fifteen times during 1 year.
Study: 33242065
Drug: PAR2 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAR2 antibody (MEDI0618)
Study: 33242065
Drug: AZ8838 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZ8838 and AZ3451 (non-peptide small molecule antagonists)
Study: 33242065
Drug: PAR2 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAR2 antibody (Fab3949)
Study: 33242457
Drug: Nevirapine dosed
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine dosed at 6 mg/kg twice daily for term neonates or 4 mg/kg twice daily for 1 week and 6 mg/kg twice daily thereafter for preterm neonates.
Study: 33242536
Drug: Olaparib for
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib for up to 10 weeks before chemotherapy
Study: 33243149
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric prilocaine (35 to 50 mg) co-administered with 2.5 mcg of sufentanil and 100 mcg of morphine
Study: 33243149
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric prilocaine with sufentanil and morphine
Study: 33243251
Drug: Thrombospondin 1
Normalized name: Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs
DrugBank: Apadamtase alfa (DB15164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombospondin 1 (TSP1) treatment
Study: 33244711
Drug: Netarsudil ophthalmic
Normalized name: netarsudil ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netarsudil ophthalmic solution 0.02% (n=8)
Study: 33246388
Drug: Urban Zen
Normalized name: Geum urbanum root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urban Zen Integrative Therapy (UZIT)
Study: 33246973
Drug: Deoxycytidine and
Normalized name: deoxycytidine
DrugBank: 2'-Deoxycytidine (DB02594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deoxycytidine and deoxythymidine therapy
Study: 33247014
Drug: Topical or
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical or systemic treatments for atopic dermatitis (AD)
Study: 33248442
Drug: Lobectomy/Ishtmusectomy (L/I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobectomy/Ishtmusectomy (L/I)
Study: 33248962
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2DE-LVEF or LVESVi and strain
Study: 33249200
Drug: ICD/cardiac resynchronization
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD/cardiac resynchronization therapy - defibrillator replacement
Study: 33249636
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment for 16 weeks
Study: 33249802
Drug: UST 130
Normalized name: ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: UST 130 mg
Study: 33249802
Drug: UST 6
Normalized name: Ustell
DrugBank: Phenyl salicylate (DB11071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UST 6 mg/kg
Study: 33249802
Drug: UST 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: UST 90 mg q12w
Study: 33249802
Drug: UST 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: UST 90 mg q8w
Study: 33250788
Drug: Behavioral paradigms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral paradigms to facilitate treatment development
Study: 33251516
Drug: Parenteral ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral ascorbic acid (1,500 mg), hydrocortisone (50 mg), and thiamine (100 mg) every 6 hours for 4 days
Study: 33251691
Drug: Eculizumab (nine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (nine infusions during the first 2 months posttransplant)
Study: 33251774
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) treatment with non-flow limiting dissection
Study: 33251774
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) treatment with flow limiting dissection
Study: 33252292
Drug: IVF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF treatment interrupted or postponed due to COVID-19
Study: 33252347
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BCTs and PSD principles
Study: 33253641
Drug: Intravesical nadofaragene
Normalized name: Nadofaragene firadenovec
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical nadofaragene firadenovec (75 mL dose, 3×10^11 viral particles)
Study: 33253997
Drug: Cabozantinib, median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib, median average daily dose 40.0 mg, treatment duration median 7.6 months
Study: 33253997
Drug: Cabozantinib initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib initiation at 60 mg/day
Study: 33256377
Drug: Eltrombopag (EPAG)
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag (EPAG) 50 mg/day to a maximum of 150 mg/day for 16 weeks
Study: 33256777
Drug: Infants born
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants born weighing < 1000 g
Study: 33256777
Drug: Infants born
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants born weighing 1000-1499 g
Study: 33256777
Drug: Infants born
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants born weighing 1500-2499 g
Study: 33256782
Drug: Babies born
Normalized name: Formula, Infant Oral Liquid [ENFAMIL ENFACARE FOR BABIES BORN PREMATURELY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Babies born weighing ≥ 2500 g
Study: 33256829
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg IV on cycle 1 day 1 and carboplatin IV AUC=5 on cycle 1 day 8; trastuzumab for HER2-positive patients
Study: 33257977
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy with fluoropyrimidine, oxaliplatin, and bevacizumab
Study: 33258792
Drug: mobile-assisted cognitive
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: mobile-assisted cognitive behavioral therapy for negative symptoms (mCBTn)
Study: 33259032
Drug: Checkpoint inhibition
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checkpoint inhibition therapy using monoclonal antibodies against PD-1 or PD-L1
Study: 33259326
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support group intervention facilitated by PSWs (10 weekly 90-minute online workshops)
Study: 33259589
Drug: Umbralisib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbralisib (800 mg/d)
Study: 33259782
Drug: TDS (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDS (120 µg/day levonorgestrel and 30 µg/day ethinyl estradiol)
Study: 33259921
Drug: Epicutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epicutaneous immunotherapy for peanut allergy
Study: 33259932
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of androgen deprivation therapy (ADT) concurrent with abiraterone acetate plus prednisone (AAP) once daily and radiation therapy (RT) to prostate and seminal vesicles
Study: 33259932
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of ADT concurrent with AAP and RT
Study: 33262134
Drug: HPN536 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPN536 (doses ranging from 0.1 to 10 mg/kg)
Study: 33262641
Drug: Tolperisone 50
Normalized name: tolperisone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolperisone 50 mg TID
Study: 33262641
Drug: Tolperisone 100
Normalized name: tolperisone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolperisone 100 mg TID
Study: 33262641
Drug: Tolperisone 150
Normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolperisone 150 mg TID
Study: 33262641
Drug: Tolperisone 200
Normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolperisone 200 mg TID
Study: 33264119
Drug: Norepinephrine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine administered during anesthesia (μg·kg-1 30 min-1)
Study: 33267919
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy (CBT-E)
Study: 33267959
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta coadministered with HP-hMG (dosage adjustments confined to HP-hMG only)
Study: 33268029
Drug: Haploidentical natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haploidentical natural killer (NK) cell infusions after autologous stem cell transplant (ASCT)
Study: 33268029
Drug: Haploidentical natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haploidentical natural killer (NK) cell infusions
Study: 33268421
Drug: PharMoG team
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PharMoG team intervention (clinical medication review)
Study: 33269549
Drug: LENT index
Approvals — FDA: no, EMA: no, PMDA: no
Description: LENT index (combination of LE index and NT-proBNP levels)
Study: 33269625
Drug: linagliptin add-on
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin add-on therapy
Study: 33270816
Drug: leukemia-specific T
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: leukemia-specific T cells (mLSTs) administered at escalating doses (0.5 to 10 × 10^7 cells per square meter)
Study: 33270832
Drug: Eculizumab discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab discontinuation
Study: 33271094
Drug: GX-188E therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: GX-188E therapeutic DNA vaccine plus pembrolizumab
Study: 33272131
Drug: PF-05230907 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05230907 at 30 μg/kg
Study: 33272131
Drug: PF-05230907 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05230907 at doses ranging from 5 to 30 μg/kg
Study: 33272982
Drug: Nivolumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) combined with Infliximab (5 mg/kg)
Study: 33272982
Drug: Nivolumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) combined with Certolizumab
Study: 33273485
Drug: Continuous weekly
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous weekly DBS CRP data
Study: 33275104
Drug: Twitter +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twitter + Fitbit treatment group
Study: 33275278
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium
Study: 33275278
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B
Study: 33275278
Drug: Oral calcium-vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral calcium-vitamin D
Study: 33276117
Drug: Type 2
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 2 inflammation treatment
Study: 33276302
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for ICAD
Study: 33276423
Drug: two-visit primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: two-visit primary vaccination schedule (two intradermal 0.1 mL rabies vaccine doses on day 0 and 7)
Study: 33276423
Drug: three-visit primary
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: three-visit primary vaccination schedule (single intradermal 0.1 mL dose on day 0, 7, and 28)
Study: 33277427
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs), 3 injections spaced 3 months apart.
Study: 33277427
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs).
Study: 33277620
Drug: VIDL induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIDL induction chemotherapy (4 cycles)
Study: 33277620
Drug: VIDL induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIDL induction chemotherapy
Study: 33277913
Drug: Tacrolimus-based immunosuppressive
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus-based immunosuppressive therapy (73.7% of recipients)
Study: 33277913
Drug: Ciclosporin-based immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin-based immunosuppressive therapy (24.3% of recipients)
Study: 33277913
Drug: Tacrolimus-based immunosuppressive
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus-based immunosuppressive therapy
Study: 33277913
Drug: Ciclosporin-based immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin-based immunosuppressive therapy
Study: 33278077
Drug: Cell-based immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-based immunotherapy
Study: 33278077
Drug: Cell-based therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-based therapies
Study: 33278125
Drug: High-dose synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose synthetic ACTH
Study: 33278125
Drug: Low-dose synthetic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose synthetic ACTH